Recent Advances in Cyclosporine Pharmacokinetics

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Although cyclosporine has been in clinical use for more than a decade, many questions persist concerning its pharmacokinetics. Gastric emptying, bile acids, and gastrointestinal motility can influence drug absorption after oral administration, but the relative importance of each of these factors and their interactions as determinants of absorption are not clear. The fraction unbound in plasma has been determined in several studies and may be associated with clinical effects. Biochemical and molecular studies have identified the specific cytochrome P‐450 enzymes that metabolize cyclosporine to its primary metabolites. The drug's basic pharmacokinetic profile has been defined and many factors have been identified that can influence clearance, such as age, hepatic function, hematocrit, and lipoprotein concentrations. With the development of sensitive and specific analytical methods, many new cyclosporine metabolites have been identified in humans. The major metabolites are present in relatively high concentrations in human blood and have some immunosuppressive activity in vitro, but their contribution to in vivo immunosuppression is not clear. 1991 Pharmacotherapy Publications Inc.

Original languageEnglish (US)
Pages (from-to)130S-134S
JournalPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Volume11
Issue number5
DOIs
StatePublished - Jan 1 1991

Fingerprint

Cyclosporine
Pharmacokinetics
Cytochrome P-450 Enzyme System
Gastrointestinal Motility
Gastric Emptying
Immunosuppressive Agents
Bile Acids and Salts
Hematocrit
Pharmaceutical Preparations
Immunosuppression
Lipoproteins
Oral Administration
Publications
Drug Therapy
Liver
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Recent Advances in Cyclosporine Pharmacokinetics. / Yee, Gary C.

In: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Vol. 11, No. 5, 01.01.1991, p. 130S-134S.

Research output: Contribution to journalArticle

@article{c70a4130df854745a35f87e7d075b3bb,
title = "Recent Advances in Cyclosporine Pharmacokinetics",
abstract = "Although cyclosporine has been in clinical use for more than a decade, many questions persist concerning its pharmacokinetics. Gastric emptying, bile acids, and gastrointestinal motility can influence drug absorption after oral administration, but the relative importance of each of these factors and their interactions as determinants of absorption are not clear. The fraction unbound in plasma has been determined in several studies and may be associated with clinical effects. Biochemical and molecular studies have identified the specific cytochrome P‐450 enzymes that metabolize cyclosporine to its primary metabolites. The drug's basic pharmacokinetic profile has been defined and many factors have been identified that can influence clearance, such as age, hepatic function, hematocrit, and lipoprotein concentrations. With the development of sensitive and specific analytical methods, many new cyclosporine metabolites have been identified in humans. The major metabolites are present in relatively high concentrations in human blood and have some immunosuppressive activity in vitro, but their contribution to in vivo immunosuppression is not clear. 1991 Pharmacotherapy Publications Inc.",
author = "Yee, {Gary C.}",
year = "1991",
month = "1",
day = "1",
doi = "10.1002/j.1875-9114.1991.tb02643.x",
language = "English (US)",
volume = "11",
pages = "130S--134S",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Recent Advances in Cyclosporine Pharmacokinetics

AU - Yee, Gary C.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Although cyclosporine has been in clinical use for more than a decade, many questions persist concerning its pharmacokinetics. Gastric emptying, bile acids, and gastrointestinal motility can influence drug absorption after oral administration, but the relative importance of each of these factors and their interactions as determinants of absorption are not clear. The fraction unbound in plasma has been determined in several studies and may be associated with clinical effects. Biochemical and molecular studies have identified the specific cytochrome P‐450 enzymes that metabolize cyclosporine to its primary metabolites. The drug's basic pharmacokinetic profile has been defined and many factors have been identified that can influence clearance, such as age, hepatic function, hematocrit, and lipoprotein concentrations. With the development of sensitive and specific analytical methods, many new cyclosporine metabolites have been identified in humans. The major metabolites are present in relatively high concentrations in human blood and have some immunosuppressive activity in vitro, but their contribution to in vivo immunosuppression is not clear. 1991 Pharmacotherapy Publications Inc.

AB - Although cyclosporine has been in clinical use for more than a decade, many questions persist concerning its pharmacokinetics. Gastric emptying, bile acids, and gastrointestinal motility can influence drug absorption after oral administration, but the relative importance of each of these factors and their interactions as determinants of absorption are not clear. The fraction unbound in plasma has been determined in several studies and may be associated with clinical effects. Biochemical and molecular studies have identified the specific cytochrome P‐450 enzymes that metabolize cyclosporine to its primary metabolites. The drug's basic pharmacokinetic profile has been defined and many factors have been identified that can influence clearance, such as age, hepatic function, hematocrit, and lipoprotein concentrations. With the development of sensitive and specific analytical methods, many new cyclosporine metabolites have been identified in humans. The major metabolites are present in relatively high concentrations in human blood and have some immunosuppressive activity in vitro, but their contribution to in vivo immunosuppression is not clear. 1991 Pharmacotherapy Publications Inc.

UR - http://www.scopus.com/inward/record.url?scp=0026014663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026014663&partnerID=8YFLogxK

U2 - 10.1002/j.1875-9114.1991.tb02643.x

DO - 10.1002/j.1875-9114.1991.tb02643.x

M3 - Article

C2 - 1745619

AN - SCOPUS:0026014663

VL - 11

SP - 130S-134S

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 5

ER -